- Home
- IBRX vs TTMI Comparison
IBRX vs TTMI Comparison
Compare IBRX & TTMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- TTMI
- Stock Information
- Founded
- IBRX 2014
- TTMI 1978
- Country
- IBRX United States
- TTMI United States
- Employees
- IBRX N/A
- TTMI N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- TTMI Electrical Products
- Sector
- IBRX Health Care
- TTMI Technology
- Exchange
- IBRX Nasdaq
- TTMI Nasdaq
- Market Cap
- IBRX 2.4B
- TTMI 2.5B
- IPO Year
- IBRX N/A
- TTMI 2000
- Fundamental
- Price
- IBRX $2.81
- TTMI $26.33
- Analyst Decision
- IBRX Buy
- TTMI Strong Buy
- Analyst Count
- IBRX 2
- TTMI 4
- Target Price
- IBRX $17.38
- TTMI $26.31
- AVG Volume (30 Days)
- IBRX 5.6M
- TTMI 533.8K
- Earning Date
- IBRX 11-12-2024
- TTMI 02-05-2025
- Dividend Yield
- IBRX N/A
- TTMI N/A
- EPS Growth
- IBRX N/A
- TTMI N/A
- EPS
- IBRX N/A
- TTMI 0.66
- Revenue
- IBRX $7,332,000.00
- TTMI $2,360,827,000.00
- Revenue This Year
- IBRX $2,572.99
- TTMI $10.68
- Revenue Next Year
- IBRX $747.59
- TTMI $5.34
- P/E Ratio
- IBRX N/A
- TTMI $39.71
- Revenue Growth
- IBRX 1218.71
- TTMI 3.51
- 52 Week Low
- IBRX $2.82
- TTMI $13.43
- 52 Week High
- IBRX $10.53
- TTMI $28.00
- Technical
- Relative Strength Index (RSI)
- IBRX 29.17
- TTMI 72.63
- Support Level
- IBRX $2.82
- TTMI $25.20
- Resistance Level
- IBRX $3.18
- TTMI $26.82
- Average True Range (ATR)
- IBRX 0.28
- TTMI 0.84
- MACD
- IBRX -0.23
- TTMI 0.07
- Stochastic Oscillator
- IBRX 1.25
- TTMI 64.78
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About TTMI TTM Technologies Inc.
TTM Technologies Inc manufactures technology solutions, including mission systems, radio frequency (RF) components/RF microwave/microelectronic assemblies, quick-turn and technologically printed circuit boards (PCB). The company is based in the United States and derives roughly half of its revenue domestically. The company organizes itself into two segments: printed circuit boards and RF&S Components. The printed circuit boards segment, which contributes the majority of revenue, offers a range of printed circuit boards as well as layout design and simulation, and testing services. TTM Technologies' products are used in manufacturing, networking, telecommunications, computing, aerospace, and medical fields.